Pivanex

SKU: orb1940702

Description

Pivanex is an orally active HDAC inhibitor and an antimetastatic and antiangiogenic agent. Pivanex downregulates the Bcr-Abl protein and enhances apoptosis.(In Vitro):In K562 cells, Pivanex (100-500 μM) exhibits significant anti-proliferation activity and enhances apoptosis and caspase activity. Pivanex (200 μM) induces enhancement in the G2-M phase, a moderate enhancement in the S phase, and a slight reduction in G0-G1 of the cell cycle.(In Vivo):Pivanex(200 mg/kg, b.i.d, daily) treatment marked delays in the end stage of disease as defined by the onset of body mass loss by 94.9%. Pivanex(200 mg/kg, b.i.d, daily) obviously improves the survival of SMN7 SMA mice by 84.6%.

Key Properties

• CAS Number: 122110-53-6
• MW: 202.25
• Purity: >98% (HPLC)
• Formula: C₁₀H₁₈O₄
• SMILES: CCCC(=O)OCOC(=O)C(C)(C)C
• Target: Apoptosis
• Solubility: In Vitro: DMSO : ≥ 100 mg/mL (494.44 mM)

Bioactivity

• In Vivo:
  Pivanex (AN9, 200 mg/kg, b. i. d, daily) significantly improves the survival of SMN7 SMA mice. Pivanex (AN9) treatment also marked delays the end stage of disease as defined by the onset of body mass loss. Animal model: SMN7 SMA mice (SMN2+/+; SMN7+/+; mSmn /). Dosage: 200 mg/kg. Administration: Oral administration, b. i. d, at 09.00 and 17.00 daily. Result: Improved the mean lifespan of treated SMN7 SMA mice by 84.6%. Delayed the onset of body mass loss in SMN7 SMA mice by 94.9%.
• In Vitro:
  Pivanex (100-500 μM) exhibits significant anti-proliferation activity in K562 cells. Pivanex (100-500 μM) also enhances apoptosis and caspase activity in K562 cells. Pivanex (200 μM)induces enhancement in the G2-M phase, a moderate enhancement in the S phase and a slight reduction in G0-G1 of the cell cycle. Pivanex (AN-9) has selective toxicity to acute leukemia and drug-resistant primary leukemia and cancer cell lines. Cell Viability Assay Cell line: K562 cells. Concentration: 100-500 μM. Incubation time: 24 hours. Result: Reduced the number of K562 viable cells significantly.100 μM Pivanex with 0.125 or 0.25 μM STI571 reduced the number of viable cells synergistically. Apoptosis Analysis Cell line: K562 cells. Concentration: 100-500 μM. Incubation time: 6-72 hours. Result: Increased the number of K562 apoptotic cells significantly. Increased the caspase activity in K562 cells significantly after only 4 h of incubation with 500 μM.

Storage & Handling

• Storage: Storage temperature: -20°C. Stability: ≥ 2 years
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

AN-9 | Pivalyloxymethyl butyrate

Quick Database Links

Gene Symbol

Apoptosis